Skip to main content
    M

    Maravai Lifesciences Holdings Inc (MRVI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.40
    -0.14 (-1.86%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Maravai Lifesciences Holdings Inc (MRVI) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Maravai Lifesciences Holdings (MRVI) trades at 5.2x sales and 5.6x book value. Its P/S of 5.2x is above its 5-year median of 2.8x. Its forward P/E is 370.4x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E370.4x
    Price to sales5.2x
    Price to book5.6x
    PEGN/A
    FCF yield-1.1%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S5.2x2.8xN/A
    P/B5.6x2.8xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 6 year ends shown, its P/S ranged from 2.1x in 2022 to 9.5x in 2020.

    Year endPriceP/EP/SP/B
    2025$3.25N/A2.5x2.2x
    2024$5.45N/A2.9x2.3x
    2023$6.55N/A3.0x2.1x
    2022$14.318.0x2.1x3.5x
    2021$41.9041.9x5.9x16.2x
    2020$28.05N/A9.5x36.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MRVI

    What is MRVI's forward P/E ratio?

    Maravai Lifesciences Holdings has a forward P/E ratio of 370.4x.

    Is MRVI stock overvalued?

    GNG's valuation label for MRVI is Overvalued.

    What is MRVI's price to sales ratio?

    Maravai Lifesciences Holdings has a price to sales ratio of 5.2x.